The deal pairs Telix’s targeted cancer therapies with ITM’s ability to make the scarce radioactive isotopes the whole field depends on — a bid to own more of a fast-growing, supply-constrained business.
A soft, flexible fiber less than half a millimeter wide combines three tools neuroscientists usually need separate devices for — a design meant to work with the brain instead of irritating it.
A concentrated compound called 7-OH — barely present in the natural kratom leaf but abundant in new commercial products — is driving opioid-like dependence and harsh withdrawal, clinics say.
A new rule swaps the term “animal tests” for “nonclinical tests,” formally recognizing lab-on-a-chip, human-cell and AI methods as valid ways to gauge a drug’s safety — without banning animal studies.
Pooling 69 trials and 150,000-plus adults, researchers found routine calcium and vitamin D supplements did little to prevent fractures or falls — with important exceptions for people who are deficient or have osteoporosis.
Olivia and Tom Walton have committed an initial $100M to Healthy Moms, Healthy Babies America. The money is small next to the problem — which is exactly why it is structured as matching capital.
A new electronic artificial urinary sphincter lets men restore bladder control at the push of a key-fob button — a potential upgrade over devices that require an awkward manual squeeze. Early results are promising, but the study is tiny.
Beyond A, B and O lies a hidden world of rare blood types. Researchers have finally pinned down the genetic source of one that eluded science since 1972 — a discovery that could save the lives of a tiny, hard-to-match group of patients.
With psychedelic therapies advancing toward the market, a public FDA hearing wrestled with a central tension: how to protect patients without building an approval system so restrictive that few can actually use them.
Thousands of clinical trials recruit at any moment, yet most eligible patients never join — and it’s usually not because they refuse. The bigger failure is an information system that buries the trials they’d qualify for.
Bundibugyo virus, a lesser-known cousin of Ebola, has caused its largest outbreak on record in Central Africa — and there’s no licensed vaccine or treatment for it.
In a 12-week pilot, people with early Huntington’s who confined eating to a daily window showed improvements in disease and nerve-damage markers — but with no control group, the researchers stress it’s far from proof.